A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of Onartuzumab (METMAB) with Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum as First-Line Treatment for Patients (PTS) with Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Annals of Oncology ◽

10.1016/s0923-7534(20)33827-8 ◽

2012 ◽

Vol 23 ◽

pp. ix445

Author(s):

H. Wakelee ◽

W. Yu ◽

K. Rittweger ◽

V.E. Paton

Keyword(s):

Lung Cancer ◽

Controlled Study ◽

Line Treatment ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of Onartuzumab (METMAB) in Combination with Paclitaxel + Cisplatin (or Carboplatin) as First-Line Treatment for Patients (PTS) With Stage IIIB or IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Annals of Oncology ◽

10.1016/s0923-7534(20)33828-x ◽

2012 ◽

Vol 23 ◽

pp. ix445 ◽

Author(s):

F.R. Hirsch ◽

D. Gandara ◽

R. Govindan ◽

V.E. Paton ◽

W. Yu

Keyword(s):

Lung Cancer ◽

Controlled Study ◽

Line Treatment ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

118TiP A multicenter, randomized, double-blind, placebo-controlled phase III trial of camrelizumab plus chemotherapy with or without radiation therapy (RT) as first-line treatment for patients with brain metastatic non-small cell lung cancer (BM-NSCLC; CTONG2003): Trial in progress

Annals of Oncology ◽

10.1016/j.annonc.2021.10.136 ◽

2021 ◽

Vol 32 ◽

pp. S1426-S1427

Author(s):

J. Yang ◽

Y. Pan ◽

F. Ning ◽

L. Lin ◽

X. Hu ◽

...

Keyword(s):

Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

First Line Treatment

Download Full-text

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.18s.lba8002 ◽

2009 ◽

Vol 27 (18S) ◽

pp. LBA8002-LBA8002 ◽

Author(s):

V. A. Miller ◽

P. O'Connor ◽

C. Soh ◽

F. Kabbinavar

Keyword(s):

Lung Cancer ◽

Locally Advanced ◽

Line Treatment ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8031 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8031-8031 ◽

Author(s):

J. S. Lee ◽

J. Ignacio ◽

C. Yu ◽

C. Zhou ◽

Y. Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Line Treatment ◽

Double Blind Trial ◽

Small Cell Lung ◽

Double Blind ◽

First Line Treatment

Download Full-text

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2012.03.011 ◽

2012 ◽

Vol 77 (2) ◽

pp. 346-352 ◽

Author(s):

Myung-Ju Ahn ◽

James Chih-Hsin Yang ◽

Jun Liang ◽

Jin-Hyoung Kang ◽

Qingyu Xiu ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Trial ◽

Line Treatment ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

Never Smoker ◽

First Line Treatment

Download Full-text

Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8061 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8061-8061 ◽

Author(s):

D. M. Kocs ◽

R. N. Raju ◽

M. A. Socinski ◽

T. E. Stinchcombe ◽

S. R. Rousey ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7576 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7576-7576 ◽

Author(s):

T. Stinchcombe ◽

D. S. Bradford ◽

C. B. Lee ◽

D. T. Moore ◽

K. M. Bakri ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8056 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8056-8056

Author(s):

Masayuki Takeda ◽

Takashi Seto ◽

Hidetoshi Hayashi ◽

Morihito Okada ◽

Koichi Azuma ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Line Treatment ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text